Biomedical Bonding Gains Funding for Bonevolent Fracture Treatment

By Julie A. Vetalice

Biomedical Bonding Gains Funding for Bonevolent Fracture Treatment

Biomedical Bonding (BMB) has secured SEK 3 million (~USD $0.3 million) in funding to fast-track the development of their composite-based universal bone fixators for fracture treatment.

"BMB’s quest is to become the first MedTech company to provide implants that adapt to fractures in real-time during surgery, as opposed to pre-manufactured metal plates," said Michael Malkoch, CEO and Founder of BMB.

In 2021, BMB received a patent in China for a novel primer formulation. The product is an enabling technology and part of the Bonevolent™ platform developed to advance strong adhesion to metal implants, for use in resin-based fixation of bone fractures and dental restoration.

Source: Biomedical Bonding

Product Labels: Upper Extremity, Lower Extremity

Tags: Funding